![After Amarin Snags Vascepa Label Expansion, Analyst Says Biopharma An Attractive M&A Target]( "After Amarin Snags Vascepa Label Expansion, Analyst Says Biopharma An Attractive M&A Target")
Christmas came early for Amarin Corporation plc (NASDAQ: AMRN) with the FDA's approval of an expanded label for its fish oil pill Vascepa ahead of a scheduled Dec. 28 decision date. H.C. Wainwright analyst Andrew Fein reiterated a Buy on Amarin with a $51 price target.
from Yahoo Finance https://ift.tt/2S0bJkD
0 comments:
Post a Comment